Development pipeline
Select programs in development, Phase 1 through Approval (removed after programs achieve approval in both US/EU)
Learn more
Novel therapies
Select Novel Therapy programs recently approved or with potential filings in the US/EU within a specified window as outlined in the Enterprise Business Review.
Learn more
2024 Key events
Major US/EU approvals and submissions and phase 2/3 clinical data presentations being planned or achieved for the year.
Learn more
U.S. patent expiry tables
Information about our pharmaceutical patent portfolio.
Learn more